公开(公告)号：US12071470B2

公开(公告)日：2024-08-27

申请号：US18172836

申请日：2023-02-22

Applicant: The Rockefeller University ,  California Institute of Technology

Inventor： Johannes Scheid ,  Michel Nussenzweig ,  Pamela J. Bjorkman ,  Ron Diskin

IPC: G01N33/569 ,  C07K16/10 ,  A61K39/00

CPC classification number: C07K16/1045 ,  C07K16/1063 ,  G01N33/56983 ,  A61K2039/505 ,  C07K2317/10 ,  C07K2317/21 ,  C07K2317/34 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/76 ,  C07K2317/92

Abstract: The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection.

公开(公告)号：US20240238623A9

公开(公告)日：2024-07-18

申请号：US17812264

申请日：2022-07-13

Applicant: ImmunityBio, Inc.

Inventor： Laurent H. Boissel ,  Hans G. Klingemann

IPC: A61K35/17 ,  A61K35/28 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K14/705 ,  C07K14/735 ,  C07K16/10 ,  C07K16/28 ,  C07K16/32 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K35/28 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70535 ,  C07K16/10 ,  C07K16/1018 ,  C07K16/1027 ,  C07K16/1063 ,  C07K16/109 ,  C07K16/2803 ,  C07K16/2827 ,  C07K16/2863 ,  C07K16/2866 ,  C07K16/2878 ,  C07K16/2887 ,  C07K16/32 ,  C12N5/0646 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: Provided are NK-92 cells expressing a chimeric antigen receptor (CAR). The CAR can comprise an intracellular domain of FcϵRIγ. Also described are methods for treating a patient having or suspected of having a disease that is treatable with NK-92 cells, such as cancer or a viral infection, comprising administering to the patient NK-92-CAR cells.

公开(公告)号：US12005119B2

公开(公告)日：2024-06-11

申请号：US18200958

申请日：2023-05-23

Applicant: The Board of Trustees of the Leland Stanford Junior University

Inventor： Eric A. Appel ,  Joseph L. Mann ,  John Klich ,  Catherine M. Kasse

IPC: A61K47/32 ,  C07K16/10

CPC classification number: A61K47/32 ,  C07K16/1063

Abstract: Polyacrylamide-based copolymers act as stabilizing excipients in formulations of antibody biopharmaceutical agents without interacting directly with the antibody or altering its pharmacokinetic properties. The polyacrylamide-based copolymers confer a substantial stability benefit to high concentration compositions of a variety of antibodies by precluding adsorption of the antibody to the interfaces of the composition, preventing undesirable aggregation events and maintaining the binding activity of the antibody. Such antibody compositions are useful in methods of administering the composition to a subject.

公开(公告)号：US11866498B2

公开(公告)日：2024-01-09

申请号：US16271410

申请日：2019-02-08

Applicant: Genentech, Inc.

Inventor： Diego Ellerman ,  Teemu T. Junttila ,  Twyla Noelle Lombana ,  Dionysos Slaga ,  Christoph Spiess

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/32 ,  A61K39/395 ,  A61K47/65 ,  A61K9/00 ,  C07K16/46 ,  C07K16/10 ,  A61P35/02

CPC classification number: C07K16/2809 ,  A61K9/0019 ,  A61K39/3955 ,  A61K47/65 ,  A61P35/00 ,  A61P35/02 ,  C07K16/1063 ,  C07K16/2803 ,  C07K16/2818 ,  C07K16/32 ,  C07K16/468

Abstract: The present invention provides bispecific antigen-binding molecules having a monovalent arm specific to a first target antigen (e.g., a T cell antigen, such as CD3) and a bivalent arm specific for a second target antigen (e.g., a tumor antigen, such as HER2). Bispecific antigen-binding molecules are useful in the treatment of disorders, such as cancer (e.g., HER2-positive cancer). The invention also features methods of producing bispecific antigen-binding molecules, methods of treating disorders using bispecific antigen-binding molecules, and compositions including bispecific antigen-binding molecules.

公开(公告)号：US20230398186A1

公开(公告)日：2023-12-14

申请号：US18452167

申请日：2023-08-18

Applicant: NantCell, Inc.

Inventor： Kayvan Niazi ,  Jeffrey Safrit ,  John H. Lee

IPC: A61K38/20 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/192 ,  A61K31/4406 ,  C07K16/10 ,  A61K31/215 ,  A61K35/17 ,  C07K14/735 ,  A61K39/12 ,  A61K31/506

CPC classification number: A61K38/2086 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/192 ,  A61K31/4406 ,  C07K16/1063 ,  A61K31/215 ,  A61K35/17 ,  C07K14/70535 ,  A61K39/12 ,  A61K31/506

Abstract: HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

公开(公告)号：US11786577B2

公开(公告)日：2023-10-17

申请号：US17475783

申请日：2021-09-15

Applicant: NantCell, Inc.

Inventor： Kayvan Niazi ,  Jeffrey Safrit ,  John H. Lee

IPC: A61K35/17 ,  A61K39/12 ,  A61K39/00 ,  A61K39/395 ,  C07K16/10 ,  A61K38/20 ,  A61K31/167 ,  A61K31/4045 ,  A61K31/192 ,  A61K31/4406 ,  A61K31/215 ,  C07K14/735 ,  A61K31/506

CPC classification number: A61K38/2086 ,  A61K31/167 ,  A61K31/192 ,  A61K31/215 ,  A61K31/4045 ,  A61K31/4406 ,  A61K31/506 ,  A61K35/17 ,  A61K39/12 ,  C07K14/70535 ,  C07K16/1063

Abstract: HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered.

公开(公告)号：US20230322947A1

公开(公告)日：2023-10-12

申请号：US17950350

申请日：2022-09-22

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Joost J. NEIJSSEN ,  Edward Norbert VAN DEN BRINK ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/40 ,  C07K16/28 ,  C07K16/10 ,  C07K16/36 ,  C07K16/00 ,  C07K16/32 ,  C07K16/12

CPC classification number: C07K16/40 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/1063 ,  C07K16/36 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/32 ,  C07K16/1271 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/53 ,  C07K2317/31 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/92 ,  C07K2317/41 ,  C07K2317/74 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/24 ,  C07K2317/71 ,  A61K2039/505

Abstract: Described herein are, proteins comprising amino acid substitutions in at least one of a first and a second polypeptide chain. Furthermore, is described the uses and methods related to said proteins.

公开(公告)号：US11760790B2

公开(公告)日：2023-09-19

申请号：US16971826

申请日：2019-02-21

Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services

Inventor： Paolo Lusso ,  Qingbo Liu ,  Peter Kwong ,  John Mascola ,  Young Do Kwon

IPC: C07K16/10 ,  A61P31/18 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/1063 ,  A61P31/18 ,  G01N33/56988 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/94 ,  G01N2333/162

Abstract: Antibodies and antigen binding fragments that specifically bind to HIV-1 Env and neutralize HIV-1 are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV-1 using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV-1 infection is disclosed.

公开(公告)号：US11760789B2

公开(公告)日：2023-09-19

申请号：US16725596

申请日：2019-12-23

Applicant: University of Maryland, Baltimore ,  The United States Government as Represented by the Department of Veterans Affairs

Inventor： Mohammad Sajadi ,  George K. Lewis ,  Anthony DeVico

IPC: A61K39/42 ,  C07K16/10 ,  A61P31/18 ,  A61K45/06

CPC classification number: C07K16/1063 ,  A61K39/42 ,  A61K45/06 ,  A61P31/18 ,  C07K16/1045 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94

Abstract: The present invention provides broadly neutralizing antibodies against HIV, compositions comprising the same and methods of use thereof.

公开(公告)号：US20230227553A1

公开(公告)日：2023-07-20

申请号：US17936047

申请日：2022-09-28

Applicant: ModeX Therapeutics

Inventor： Ronnie Rong WEI ,  Ling XU ,  Zhi-Yong YANG ,  Edward SEUNG ,  Gary J. NABEL

IPC: C07K16/28 ,  A61P35/00 ,  C07K16/30 ,  C07K16/10 ,  A61P31/12

CPC classification number: C07K16/2809 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/2818 ,  C07K16/2878 ,  C07K16/2866 ,  A61P35/00 ,  C07K16/3076 ,  C07K16/1063 ,  A61P31/12 ,  C07K2317/31

Abstract: Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells; chimeric antigen receptors (CARs); immune cells; pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.